- Home
- ATOS vs AISP Comparison
ATOS vs AISP Comparison
Compare ATOS & AISP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- AISP
- Stock Information
- Founded
- ATOS 2009
- AISP 2006
- Country
- ATOS United States
- AISP United States
- Employees
- ATOS N/A
- AISP N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- AISP Blank Checks
- Sector
- ATOS Health Care
- AISP Finance
- Exchange
- ATOS Nasdaq
- AISP Nasdaq
- Market Cap
- ATOS 96.8M
- AISP 107.6M
- IPO Year
- ATOS 2012
- AISP N/A
- Fundamental
- Price
- ATOS $0.89
- AISP $4.40
- Analyst Decision
- ATOS Strong Buy
- AISP Strong Buy
- Analyst Count
- ATOS 3
- AISP 2
- Target Price
- ATOS $7.13
- AISP $9.00
- AVG Volume (30 Days)
- ATOS 611.2K
- AISP 479.4K
- Earning Date
- ATOS 05-13-2025
- AISP 05-23-2025
- Dividend Yield
- ATOS N/A
- AISP N/A
- EPS Growth
- ATOS N/A
- AISP N/A
- EPS
- ATOS N/A
- AISP N/A
- Revenue
- ATOS N/A
- AISP $23,050,213.00
- Revenue This Year
- ATOS N/A
- AISP $34.30
- Revenue Next Year
- ATOS N/A
- AISP $59.47
- P/E Ratio
- ATOS N/A
- AISP N/A
- Revenue Growth
- ATOS N/A
- AISP 87.41
- 52 Week Low
- ATOS $0.55
- AISP $1.90
- 52 Week High
- ATOS $1.74
- AISP $7.66
- Technical
- Relative Strength Index (RSI)
- ATOS 64.44
- AISP 55.98
- Support Level
- ATOS $0.78
- AISP $3.68
- Resistance Level
- ATOS $0.92
- AISP $4.19
- Average True Range (ATR)
- ATOS 0.06
- AISP 0.24
- MACD
- ATOS 0.01
- AISP 0.04
- Stochastic Oscillator
- ATOS 81.82
- AISP 84.29
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About AISP Airship AI Holdings Inc.
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where they need it, using a highly secure permission-based architecture.